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Abstract
Hemin is a powerful in vitro inducer of low-density lipoprotein (LDL) oxidation, implicated in development of
atherosclerosis. To support the proposed role of hemin in atherogenesis, the question of whether hemin has any chance of
getting together with LDL in vivo, must be addressed. A stopped-flow technique was employed in order to investigate the
fast kinetics of hemin binding to LDL and to other plasma hemin-binding proteins: high-density lipoprotein (HDL), albumin
and hemopexin. Based on the measured rate constants of hemin association with and dissociation from each of these
proteins, time-dependent hemin distribution in plasma was analyzed. The analysis shows that as much as 80% of total hemin
binds initially to LDL and HDL, the plasma components which are most susceptible to oxidation. Only then hemin partially
transfers to the antioxidants albumin and hemopexin. The half time of the hemin^LDL complex in plasma, initially
comprising 27% of total hemin, was more than 20 s. Not only transient, but also oxidatively active steady-state hemin^
lipoprotein complexes in plasma were both predicted from the kinetic analysis and found in experiment. Our data suggest
that the hemin^LDL complex may exist in vivo and that its oxidative potential should be considered pro-
atherogenic. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Since oxidation of low-density lipoprotein (LDL)
was considered to play a major role in development
of atherosclerosis [1], great attention was given to
searching for in vivo initiators of LDL oxidation.
Several researchers have pointed out that hemin
is an e¡ective in vitro inducer of LDL oxidation
[2^5]. The hemin oxidation, producing a variety of
LDL lipid oxidation products and apo B crosslink-
ing, turns the LDL recognizable by the macrophage
scavenger receptor(s). Consequently, formation of
macrophage-derived foam cells occurs [2^5]. Since
appearance of the foam cells in vascular intima is
an early sign of atherogenesis [6], the hemin-induced
oxidation has been suggested as a possible way of
generating atherogenic, oxidized LDL in the body.
Recent epidemiological works determining sus-
ceptibility of LDL to oxidation as one of the risk
factors for atherosclerosis employ in their assays
hemin as an oxidation inducer, an alternative to cop-
per [7,8]. The authors’ decision to use hemin instead
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of copper may stem from realizing the very limited
availability of copper on the one hand, and the abun-
dance of hemin in the body, on the other hand.
Although it is doubtful that free copper and LDL
meet together in the body [9], most of the studies
on the biological e¡ects of oxidized LDL are still
using copper to produce the oxidized LDL. In order
to avoid such a situation and to justify the use of
hemin for studying LDL oxidation, the question of
whether hemin has any chance of getting together
with LDL in vivo must be addressed.
Globin-free hemin (iron(III)-protoporphyrin IX)
may appear in plasma due to hemin release from
extracorpuscular hemoglobin upon red cell rupture,
which is not a rare event under various conditions
[10]. Of note is that hemolysis features experimental
hypercholesterolemia in rabbits, the most common
model for atherosclerosis [11]. Alternatively, the plas-
ma hemin could stem from regular intracellular he-
moglobin degradation, which ¢rst leads to accumu-
lation of globin-free hemin in red cell membrane
followed by the hemin dissociation from the mem-
brane and binding with plasma proteins [12]. The
currently held view is that human serum albumin
(HSA) and hemopexin (HPX) serve as the only traps
of the toxic plasma hemin, thereby ensuring its com-
plete clearance by transportation to the liver [13,14].
Since it is agreed that by possessing high-a⁄nity sites
for hemin these two proteins protect red blood cell
from oxidative damage [13], the same view was au-
tomatically extended also to the protection of plasma
constituents by HSA and HPX.
Our previous kinetic study [15] altered this view by
demonstrating the active involvement of LDL in
hemin transport from the erythrocyte membrane to
HSA. HSA was not capable of preventing oxidative
damage of LDL by the transient hemin [15]. The
recent study by Camejo et al. [5] indicated that
high-density lipoprotein (HDL) can also associate
with hemin and undergo lipid oxidation. Although
the above data hint that LDL and HDL may partic-
ipate in hemin transport in plasma, a complete pic-
ture of the time-dependent distribution of hemin
among plasma constituents is missing. The present
study, using the kinetic approach, attempts to clarify
the fate of submicromolar levels of hemin in plasma,
considering the four hemin-binding components
LDL, HDL, HSA and HPX.
Based on stopped-£ow £uorescence measurements
of rate constants of hemin association with and dis-
sociation from each of the four plasma proteins, we
built a quantitative model of the time-dependent
hemin distribution in the plasma. Both our model
and its experimental examination proved participa-
tion of the lipoproteins in hemin transport in plasma.
Moreover, both the model and the experiment show
the presence of an oxidatively active steady-state
hemin^LDL complex in whole plasma. Our data
suggest that hemin should be indeed considered
as a trigger of LDL oxidative damage in whole plas-
ma.
2. Materials and methods
2.1. Materials
Human serum albumin (HSA; essentially globulin
free), bovine hemin, 5-dimethylaminonaphthalene-1-
sulfonyl (dansyl) chloride, and other chemicals were
from Sigma, St. Louis, MO. Human low- and high-
density lipoproteins (LDL and HDL, respectively)
were isolated from the blood of healthy donors by
sequential ultracentrifugation as described [16,17].
The lipoproteins were extensively dialyzed to remove
plasma antioxidants, EDTA and potassium bromide.
The concentration of LDL and HDL was determined
as protein concentration by the Lowry method [18].
Hemopexin (HPX) isolated from the rabbit plasma
[19] was a generous gift from Dr. Ann Smith, Uni-
versity of Missouri-Kansas City. Throughout the
text, the word ‘protein’ designates the lipoproteins
LDL and HDL in addition to HSA or HPX.
2.2. Protein labeling
Proteins were covalently labeled by a dansyl £uo-
rophore [20]. Dansyl chloride in acetone (at a ¢nal
concentration of 16 WM, less than 1% acetone in
sample) was added to 0.4 mg/ml protein in 5 mM
NaHCO3-containing saline. The mixture was incu-
bated for 60 min on ice, followed by dialysis against
PBS to remove unbound £uorescent dye. This pro-
cedure produced mildly labeled proteins. For exam-
ple, in the case of LDL, about 8^10% of the available
amino groups were labeled [21].
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2.3. Heme solutions
Commercial hemin was dissolved in 80% dimethyl
sulfoxide (DMSO). Undissolved remains were re-
moved by centrifugation. The concentration of hem-
in in this stock solution was determined using the
extinction coe⁄cient O403 = 170 mM31 cm31 in 80%
DMSO [22]. A working aqueous hemin solution, re-
ferred throughout the text as ‘aquohemin’ [23], was
prepared by diluting the DMSO stock solution into
50 mM sodium phosphate (pH 7.4) bu¡er. Since
aquohemin is a monomers and dimers mixture, the
monomer/dimer ratio of the particular solution was
calculated according to the equation of Brown et al.
[24]. In order to employ a solution containing only
monomeric heme, we used CO-heme solutions. For
the production of CO-heme, the bu¡er was pre-equi-
librated with 100% CO gas for 20 min. Several gran-
ules of dry sodium dithionite followed by hemin (in
0.1 M NaOH) were sequentially added. Concentra-
tion of CO-heme was determined using O407 =
147 mM31 cm31 [23]. The CO-heme solution was
utilized within 30 min after preparing.
2.4. Kinetic measurements
Time course of protein binding with aquohemin or
CO-heme was followed by the quenching of a protein
£uorophore, either an intrinsic tryptophanyl or a
dansyl label, by heme, which occurs via a radiation-
less energy transfer mechanism. Because energy
transfer can occur only between chromophores in
juxtaposition [25], the quenching of £uorescence in-
tensity served as an indication for heme binding with
a protein. Recovery of £uorescence indicated heme
dissociation from a protein. Di¡erence in the absorp-
tion spectra of CO-heme, hemin monomer and hem-
in dimer, although in£uencing e⁄ciency of energy
transfer, has no signi¢cance for measuring the ki-
netics of heme binding and dissociation. Fast kinetics
was measured on a stopped-£ow module SFM-3 op-
erated by the MPS/Bio-Kine software (Bio-Logic;
Science Instruments, France). Reactants were in
50 mM phosphate bu¡er, pH 7.4. Module syringes
and cuvette were thermostated at 37‡C. Excitation
and emission wavelengths were selected by a mono-
chromator and a cuto¡ ¢lter, respectively. The exci-
tation wavelength and emission region were 285/
s 305 nm for intrinsic £uorescence measurements,
and 350/s 495 nm for dansylated proteins. Experi-
mental time course of changes in £uorescence inten-
sity was ¢tted by one- or multi-exponential curves.
Statistic evaluation of ¢tted curves was done based
on M2 criteria.
A system of di¡erential equations, modeling the
time-dependent hemin distribution in the plasma,
was numerically solved using the Gepasi 3.10 soft-
ware (Copyrightz Pedro Mendes, 1997).
2.5. Steady-state measurements of hemin distribution
and LDL oxidation
Human plasma samples were supplemented with
10 WM hemin from a stock solution in 80% DMSO
(less then 0.5% DMSO ¢nal concentration) and con-
trol samples were supplemented with a respective
amount of DMSO. The samples were incubated at
37‡C for 15 min and subjected to sequential ultra-
centrifugation at 4‡C. In order to avoid loss of pro-
tein-bound hemin, the resulting fractions did not
undergo dialysis. Absorbance spectra (370^460 nm)
in the fractions of LDL, HDL and lipid-de¢cient
plasma were measured using a GBC UV/Vis 920
spectrophotometer (GBC Scienti¢c Equipment, Dan-
denong, Australia). The LDL fractions isolated from
the hemin-containing and hemin-lacking plasma
samples were incubated at 37‡C overnight in the
presence of 20 WM hydrogen peroxide. LDL lipid
peroxidation was estimated by measuring UV ab-
sorbance spectra, and analysis of lipid peroxidation
products was performed based on the data reported
in [26].
3. Results
3.1. Rates of hemin binding with plasma proteins
Since only monomeric hemin is oxidatively active
[27], we were interested in following the binding ki-
netics of hemin monomers. Although CO-heme is
monomeric in water, CO shielding two iron coordi-
nations may a¡ect heme binding with proteins. In
order to verify whether CO-heme behaves as hemin
does, we compared the CO-heme binding to proteins
with that of aquohemin.
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The time course of the quenching of LDL £uores-
cence by aquohemin was much better ¢tted with a
two-exponential curve than with a one-exponential
one (Fig. 1A), serving as evidence for the distinct
modes of hemin monomer and dimer binding with
LDL. In contrast, the trace of LDL £uorescence
quenching by CO-heme was satisfactory ¢tted with
a one-exponential curve (Fig. 1B), indicating a single
mode of CO-heme monomer binding. The rate con-
stant for CO-heme binding with LDL was closely
similar to that of the fast component of the LDL^
aquohemin binding (Table 1), suggesting faster LDL
binding with the hemin monomer than with the
dimer. Our data suggest that the pseudo-¢rst-order
rate constant of CO-heme binding to LDL faithfully
represents the faster component of aquohemin bind-
ing. This enables us to rely on practical measure-
ments of aquohemin binding to LDL as an accurate
means for studying hemin monomer binding to LDL.
Upon analyzing the kinetics of hemin binding with
either HDL, HPX or HSA, a marked closeness was
observed between the rate constant values of CO-
heme binding and the faster component of aquohe-
min binding (Table 1). This allows us, as in the case
of LDL, to relate to the faster component of aquo-
hemin binding as the pseudo-¢rst-order rate con-
stants for hemin monomer binding to the above pro-
teins.
In order to get the bimolecular rate constant for
hemin^protein binding, the kinetics of the quenching
of protein £uorescence was measured at various pro-
tein concentrations. Traces on Fig. 2A show such
measurements for HDL^hemin binding. The ob-
served pseudo-¢rst-order rate constants were then
plotted against the protein concentration (Fig. 2B)
and a bimolecular rate constant was obtained from
the slope of the ¢tting line. This procedure was sim-
ilarly applied for LDL, HSA and HPX. The second-
order rate constants for all the four plasma proteins
are listed in Table 2.
3.2. Hemin dissociation from plasma proteins
In order to measure the rate of hemin dissociation
from plasma proteins, a complex of hemin with each
dansyl-labeled protein was produced and mixed in a
stopped-£ow experiment with a 15-fold excess of the
same but non-labeled protein. The latter served to
trap the hemin dissociated from the dansylated pro-
tein^hemin complex. Fig. 3 shows the kinetics of
hemin dissociation from LDL and HDL, expressed
by recovery of the dansyl label £uorescence intensity.
These time courses were best ¢tted with two-expo-
nential curves. Respective rate constants and ampli-
tudes of each exponent are listed in Table 2. In con-
trast to lipoproteins, the hemin dissociation from
HPX and HSA was much longer (not shown) and
the traces were well simulated by one-exponential
Fig. 1. Pseudo-¢rst-order kinetics of hemin^LDL binding. Time
course of quenching of LDL intrinsic £uorescence by either
aquohemin or CO-heme was measured at 37‡C. Fluorescence
intensities were normalized to a maximal value. (A) LDL,
0.03 WM; total aquohemin, 1.07 WM; aquohemin monomer,
0.07 WM. (B) LDL, 0.055 WM; CO-heme, 0.25 WM. Since LDL
has a total of about 50 hemin binding sites, the concentration
of LDL binding sites in these experiments is in excess over
hemin concentration. Because CO-heme is a weaker quencher
of protein intrinsic £uorescence than hemin, the experiment
shown in A was done at higher LDL and heme concentrations
than those in B. The experimental traces were ¢tted by one-ex-
ponential (solid lines in A and B) and two-exponential (dashed
line in A) curves. The respective rate constants, amplitudes and
M2 values are presented in Table 1.
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curves rather than by two-exponential ones (Table
2).
Obtaining the rate constants for hemin association
with and dissociation from the proteins, we were able
to calculate equilibrium binding constants (Table 2).
The product of the binding constant multiplied by
reference plasma concentration of the protein [28]
expresses the equilibrium hemin distribution between
the major hemin binding components in plasma
(Table 2).
3.3. Analysis of the time-dependent hemin distribution
between plasma proteins
Based on the measured kinetic parameters, a mod-
el for hemin distribution between the plasma proteins
could be constructed. Assuming an independent
hemin interaction with each of the plasma proteins
and no interaction between the proteins, the follow-
ing reactions, describing the fate of hemin in plasma,
could be written:
Pi1  h3
ki1
ki31
Pi1h;
Pi2  h3
ki1
ki32
Pi2h; i  1; T4 1
Pi1 designates a hemin-binding plasma protein, ei-
ther LDL, HDL, HSA or HPX, having a bimolecu-
lar association rate constant ki1 and a monomolecu-
lar dissociation rate constant ki31 ; P
i
2 is a population
of either LDL or HDL having the same ki1 associa-
tion rate constant but another monomolecular disso-
ciation rate constant ki32 ; h is hemin; P
ih is a hem-
in^protein complex. The rate constant and amplitude
Table 1
Pseudo-¢rst-order rate constants for binding of aquohemin and CO-heme with plasma proteins
Protein Aquohemin CO-heme
one-exponential ¢t two-exponential ¢t one-exponential ¢t
k1 (M2) K1/k1 K2/k2 (M2) k1 (M2)
LDL 103 (4U1034) 0.73/781 0.27/44 (1U1034) 901 (1U1034)
HDL 64 (3U1034) 0.48/610 0.52/48 (1U1034) 735 (7U1035)
HSA 2.2 (3U1034) 0.73/5.3 0.27/0.4 (5U1035) 4.7 (3U1036)
HPX 46 (3U1034) 0.71/105 0.29/16 (3U1035) 89 (3U1036)
The experiments were done as described in Fig. 1. Rate constants k (bold numbers) are in s31 ; K is a relative amplitude of the respec-
tive exponent; M2 (in parentheses) shows accuracy of simulation.
Fig. 2. Bimolecular rate constant of HDL^hemin binding. (A)
Time course of HDL intrinsic £uorescence quenching by hemin
was measured at 37‡C and at the following HDL concentra-
tions: 0.082 WM (1), 0.122 WM (2), 0.163 WM (3) and 0.204 WM
(4). Aquohemin total concentration was 1.3 WM and aquohemin
monomer 0.076 WM. Fluorescence intensities were normalized
to a maximal value. The kinetic curves were simulated by two-
exponential ¢tting. (B) The faster rate constants (kobs) were
plotted against HDL concentration. The slope of a linear ¢t
gives a bimolecular rate constant for HDL^hemin binding.
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values are listed in Table 2. Concentrations of the
protein populations with di¡erent dissociation rates
were calculated as Pi1  Ki31Pi and Pi2  Ki32Pi. Cor-
responding di¡erential equations for the rate of the
hemin^protein complex formation were:
d Pih=dt  ki1Pih3Ki31ki31  Ki32ki32Pih;
i  1; T4 2
For HSA and HPX, the amplitudes Ki32 are zero
and the amplitudes Ki31 equal 1. The system (Eq. 2)
was numerically solved, taking normal plasma con-
centrations of the proteins (Table 2) as Pi(t = 0). The
solution curves showing evolution of each of the
plasma protein complexes with hemin are presented
in Fig. 4, in short (A) and long (B) time scales.
3.4. Formation and dissociation of hemin^LDL
complex in whole plasma
In order to evaluate correctness of the above mod-
el for the hemin^LDL complex, we separated LDL
from all the other plasma proteins by ultracentrifu-
gation. Both fractions were dialyzed to remove KBr
and low-molecular-mass components. LDL was la-
beled by dansyl as described in Section 2 and then
mixed back with the rest of the plasma. The LDL-
dansyl £uorescence time course in whole plasma,
when mixed in stopped £ow with aquohemin, is
shown in Fig. 5. A fast hemin binding to LDL and
its slow release from LDL to other plasma proteins
were observed. The dashed line is a reversed time
course of the hemin^LDL complex as simulated in
Fig. 4. The fact that about the same lifetime of the
hemin^LDL complex was observed in the experiment
and obtained from the analysis suggests the correct-
ness of the model.
Table 2
Rate and equilibrium constants and hemin equilibrium distribution between plasma proteins
Proteina k1 (M31 s31) k31 and k32 b (s31) Ka = k1/k31 c (M31) [P]d (M) Hemin distributione (%)
LDL 5.7U109 4.5U1031 (0.65) 1.3U1010 1.6U1036 2.4
4.6U1032 (0.35) 1.2U1011
HDL 1.5U109 5.1U1032 (0.90) 2.9U1010 1.4U1035 18.6
8.0U1033 (0.10) 1.9U1011
HSA 6.5U106 3.3U1033 (1.0) 2.0U109 7.4U1034 44
HPX 1.3U108 1.9U1033 (1.0) 6.8U1010 1.8U1035 35
aThe following molecular masses of the proteins were used for calculations: LDL, 512 kDa (apo B); HDL, 175 kDa (calculated from
the molecular masses and relative contributions of apo A proteins); HSA, 67 kDa; HPX, 57 kDa.
bThe k32 values for LDL and HDL are shown below the k31 values. The numbers in parentheses show relative amplitudes (K) of the
respective rates. HSA and HPX have each only one dissociation rate.
cThe secondary binding constants Ka for the proteins with two dissociation rates were calculated as k1/k32.
d[P] is a reference plasma concentration of the protein.
eHemin distribution between the speci¢ed proteins Pi was calculated as
P
mKmK
i
amPi=
P
m;iKm KiamPi; m  1; 2; i  1; T4:
Fig. 3. Hemin dissociation from LDL and HDL. A complex of
a labeled lipoprotein (either LDL or HDL) with hemin was
produced by addition of monomeric hemin (from stock in 80%
DMSO), with gentle stirring, to a dansyl-labeled lipoprotein
(100 Wg/ml) and incubated at 37‡C for 5 min. This sample was
then mixed in a stopped-£ow experiment with a 15-fold excess
of the same but non-labeled lipoprotein and recovery of the
dansyl £uorescence at 37‡C was followed. Fluorescence inten-
sities were normalized to maximal values. Final hemin concen-
tration in the complex with the labeled LDL was 0.1 WM, and
0.2 WM with the labeled HDL.
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3.5. Steady-state hemin^lipoprotein complex in whole
plasma and LDL oxidation
The analysis presented in Table 2 and Fig. 4 sug-
gests that some residual hemin remains associated
with lipoproteins in steady state. To ¢nd out if this
is indeed so, whole plasma was supplied with hemin
at a ¢nal concentration of 10 WM. This concentration
is about a half of the reference HPX level in the
plasma [28]. Following a 37‡C incubation for
15 min (the time interval su⁄cient to achieve
steady-state hemin distribution in plasma, see Fig.
4), the lipoproteins were isolated from the plasma
by sequential ultracentrifugation. Sodium dodecyl
sulfate^polyacrylamide gel electrophoresis revealed
no detectable albumin or hemopexin in the lipopro-
tein fractions (not shown). Control plasma samples,
Fig. 4. Analysis of time-dependent hemin distribution between
plasma proteins. Kinetics of hemin distribution between individ-
ual proteins is shown in a short (A) and extended (B) time
scales. The curves presented are the solution of system (2) of
di¡erential equations.
Fig. 5. Hemin transition via LDL in whole plasma. A sample
containing dansyl-labeled LDL (¢nal concentration of 20 Wg/ml)
and non-labeled LDL-de¢cient plasma (¢nal 1.7 mg/ml) was
mixed with aquohemin (¢nal 1.13 WM) at 37‡C and the dansyl
£uorescence intensity changes were followed (a trace, left y
axis). Fluorescence intensities were normalized to a maximal
value. The dashed line (right y axis) is a reversed time course
of the hemin^LDL complex as simulated in Fig. 4.
Fig. 6. Soret spectra of the fractions separated from hemin-con-
taining plasma. Plasma samples without and with 10 WM mono-
meric hemin added underwent sequential ultracentrifugation
and the fractions of LDL, HDL and lipoprotein-de¢cient plas-
ma were separated. Di¡erence spectra of these fractions ob-
tained from the hemin-containing plasma (respective fractions
from hemin-lacking plasma served as a reference) were meas-
ured in a 1-cm pathway cuvette. The spectrum of lipid-de¢cient
plasma (1) is presented in the real scale of optical density, while
the spectra of HDL (2) and LDL (3) were multiplied by 6 and
12, respectively, in order to ¢t the same scale. This is a reason
for increased noise/signal ratio in the spectra (2) and (3).
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to which no hemin was added, were subjected to the
same treatment. The di¡erence spectra of representa-
tive experimental and control samples in the Soret
region are shown in Fig. 6. The bulk of hemin was
bound to components in the lipoprotein-de¢cient
fraction. Spectrum 1 was analyzed as a superposition
of hemin^hemopexin and hemin^albumin spectra,
showing about equal concentrations of these hem-
in^protein complexes. The HDL fraction showed a
well-resolved spectrum 2, identical to that previously
reported for a hemin^lipoprotein complex [3]. The
spectrum 3 of the LDL fraction, although having a
poor signal/noise resolution, clearly showed the pres-
ence of a steady-state hemin complex with LDL.
In order to evaluate an oxidative potential of the
residual hemin bound to LDL, the experimental
(hemin-containing) and control (hemin-lacking)
LDL samples were subjected to an overnight incuba-
tion with hydrogen peroxide. The representative UV
di¡erence spectrum of these samples, shown in Fig.
7, indicates formation of lipid peroxidation products.
Component analysis, based on the known extinction
coe⁄cients [26], revealed appearance of lipid hydro-
peroxides (3.7 mol/mol LDL), 7-ketocholesterol (7.1
mol/mol LDL) and dienals (0.5 mol/mol LDL).
These data suggest that residual hemin bound to
LDL in whole plasma is capable of oxidative dam-
aging LDL under conditions of oxidative stress.
4. Discussion
The results of the present study show that of the
four plasma proteins expected to be involved in hem-
in transport, LDL binds hemin faster than any other
proteins (Tables 1 and 2). The association rates de-
creased in the following order: LDLsHDLs
HPXsHSA. LDL also released hemin faster than
other proteins^the dissociation rates were: LDLs
HDLsHSAsHPX (Table 2). We conclude from
these results that lipoproteins serve as a primary
trap for aqueous hemin. Several laboratories re-
ported kinetic parameters for hemin association
with and dissociation from HSA and HPX. Despite
some variations among their values, our data fall
within the reported range [29^31]. To the best of
our knowledge, no kinetic data on hemin binding
to lipoproteins were previously available.
Hemin dissociation from the proteins HSA and
HPX is a one-exponential process. This result suits
the presence of a single binding site in HPX [31] and
suggests that at submicromolar hemin concentrations
expected in plasma, the measured kinetics re£ects
binding with a major binding site in HSA [29]. Un-
like the single kinetics of hemin association with both
LDL and HDL, the kinetics of hemin dissociation
from these lipoproteins was best ¢tted by two-expo-
nential curves, indicating heterogeneous sites of at
least two classes (Fig. 3 and Table 2). These data
suggest that following primary binding to homoge-
nous lipoprotein sites, hemin may partially move to
other, initially segregated sites. Based on literature
data [30,32], it may be assumed that the faster dis-
sociation kinetics is related to lipid components,
whereas the slower dissociation relates to protein
sites on the lipoprotein particles. Alternatively, hem-
in may bind simultaneously to lipid and protein sites
of lipoproteins, but the protein sites, similar to those
Fig. 7. UV spectrum of LDL lipid oxidation products. The
LDL fractions obtained from hemin-containing and hemin-lack-
ing plasma samples (see Fig. 6) were exposed to overnight incu-
bation with 20 WM H2O2 at 37‡C. Following the incubation,
the samples were diluted 10-fold in a 1-cm pathway cuvette and
a di¡erence spectrum was measured (hemin-lacking fraction
served as a reference). The spectrum was ¢tted with three Gaus-
sian peaks.
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in globin or HPX [23,31], may undergo a secondary
iron chelation or conformational changes. These
changes may strengthen hemin binding, slowing
down dissociation rates.
The hemin^HSA binding constant measured in
this study at 37‡C is in agreement with the reported
values, also obtained from kinetic data, considering
the fact that the latter were measured at room tem-
perature [23,29]. However, the hemin^HPX binding
constant obtained in the present study was three or-
ders of magnitude lower than the previously reported
one [33]. This di¡erence may be explained by the fact
that the a⁄nity calculated from equilibrium heme
distribution between HPX and globin as it was
done by Hrkal et al. [33] re£ects the equilibrium be-
tween intermediate states of the hemin-bound pro-
teins rather than between ¢nal hemin^protein com-
plexes (see Appendix A).
The equilibrium constants of 1010^1011 M31 for
hemin^lipoprotein binding, obtained from our ki-
netic data, are 3^4 orders of magnitude higher than
the a⁄nity estimated from the quenching of LDL
steady-state £uorescence by increasing hemin concen-
trations (data not shown). Similar low binding con-
stants were recently reported by Camejo et al. [5]
who also employed the steady sate titration method.
The di¡erence between the kinetic and equilibrium
approaches is that the kinetic measurements under
our conditions determine the a⁄nity of primary hem-
in binding sites on LDL and HDL particles, while
the equilibrium method, which saturates the lipopro-
tein sites, take into consideration not only the high
a⁄nity sites but the majority of secondary sites (up
to 50 in LDL [5]) with much lower a⁄nity. To our
understanding, the kinetic approach better re£ects
the in vivo situation where the ratio of hemin/lipo-
protein concentrations is low.
Determination of the kinetic parameters for LDL,
HDL, HSA and HPX allowed us to construct a
quantitative model of time-dependent hemin distri-
bution among the above plasma proteins (Fig. 4).
The most surprising result from this model is that
the ¢rst seconds after hemin appearance in plasma,
more than 80% of this powerful oxidizer binds to
lipoproteins, the most oxidatively intolerant plasma
components, and only the remaining 20% binds to
antioxidative HSA and HPX (Fig. 4). LDL, due to
its fast hemin association rate, initially binds about a
fourth (27%) of hemin appearing in plasma and the
hemin^LDL complex decays with a half time of 24 s
(Fig. 4). This analysis was con¢rmed by the exper-
imental time course of the hemin^LDL complex in
plasma (Fig. 5). HDL, reaching its maximal satura-
tion by hemin (55% of total hemin in plasma), re-
leases hemin slower than LDL and thus, within the
¢rst 50 s after hemin encounter, HDL is a major
hemin carrier in plasma. HPX and HSA then slowly
remove most of the hemin from the lipoproteins (Fig.
4). Nevertheless, both analysis of the kinetic data
(Table 2 and Fig. 4) and the experiment (Fig. 6)
indicate that besides the transient hemin association
with lipoproteins, residual hemin stays with LDL
and HDL. The equilibrium hemin^LDL and hem-
in^HDL complexes comprise about a ¢fth of the
plasma hemin. Similar data on steady-state hemin
distribution in plasma was recently reported by Ca-
mejo et al. [5], although the values are incomparable
due to the use of di¡erent conditions. Whereas the
above authors used 5-fold diluted plasma and hemin
concentrations that were in extreme excess over the
concentration of HPX and even of HSA, in our
steady-state experiments hemin was half of HPX
reference level [28] and much lower than that of
HSA level. Our conditions were chosen in order to
be as close as possible to reality and allowed check-
ing hemin^lipoprotein binding under conditions
when vacant HPX and HSA binding sites are avail-
able.
While in the present study only single-pulse kinetic
or steady-state experiments were performed, in the
body hemin appears in the plasma continuously. It
was of interest to calculate a hemin level in lipopro-
teins, both transient and in steady state. It is possible
to assess these levels by considering at least one hem-
in source, namely red cell membrane-associated hem-
in, in which steady-state concentration in red cell
membrane was taken as 4U105 hemin molecules
per erythrocyte [12]. According to our calculations,
considering about half of the extractable hemin lipid-
embedded, about 2 WM hemin are transferred via
lipoproteins and about 0.5 WM hemin still resides
in lipoproteins at steady state. Further kinetic infor-
mation on heme clearance from all the four plasma
proteins to tissues will allow estimation of the actual
steady-state level of hemin within the plasma pro-
teins.
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Since hemin is a powerful in vitro LDL oxidizer,
our data on its availability in LDL-bound form in
plasma is of high importance. Oxidative potential of
hemin, moving via LDL from red cell membrane to
HSA, has been demonstrated in our previous work
[15]. In those experiments, the hemin-in-transit in-
duced moderate apo B crosslinking and thiobarbitu-
ric acid reactive substances (TBARS) formation. The
present work shows that even in whole plasma some
hemin resides within LDL. Therefore, examination
of the oxidative potential of that residual hemin to-
ward LDL was necessary. It turned out that addition
of hydrogen peroxide, despite the presence of all the
naturally occurring low-molecular-mass plasma anti-
oxidants (the samples were not subjected to dialysis
in order not to lose LDL-bound hemin), resulted in
appearance of LDL lipid peroxidation products in
the hemin-containing samples (Fig. 7). The amount
of hydrogen peroxide added (20 WM) falls in the
range of 2.5 to 40 WM reported for plasma of healthy
people and cardiac patients [34^36]. Our data suggest
that in plasma, hemin-in-transit and residual hemin
are capable of inducing LDL oxidation and hemin
therefore should be considered as an atherogenic
agent. Camejo et al. [5] also reported hemin-induced
LDL oxidation, as documented by TBARS, conju-
gated dienes and the oxidative product of esteri¢ed
arachidonic acid, isoprostane 8-epi-PGF2K. The
LDL, oxidized by hemin in diluted plasma, was rec-
ognized and degraded by macrophages [5]. Neverthe-
less, these data should be cautiously interpreted be-
cause the authors used extremely high hemin and
hydrogen peroxide concentrations. Our data indicate
that a large portion of the lipoprotein-associated
hemin resides in HDL (Table 2 and Fig. 4). Hemin
is shown to induce HDL oxidation as well [5].
Although oxidized HDL loses its anti-atherogenic
properties [37], HDL seems to play a role of a ‘sac-
ri¢cing’ antioxidant by preventing the much more
dangerous oxidation of LDL.
Discovering the fact that in addition to HPX and
HSA lipoproteins also participate in hemin transport
opens new horizons in studying heme-regulated cell
function. Many works [38^40] have reported that
hemin regulates many cellular key processes, like
transcription, translation, cell di¡erentiation and im-
mune response. Most of the cells in the body express
LDL receptors for the purpose of cholesterol and
fatty acids supply [41]. Many cells also interact
with HDL to e¥ux cholesterol [41]. In light of our
results, one may propose that cellular LDL uptake
and cell^HDL contacts serve as a route for hemin
transfer into the cell.
Considering the lipoproteins as participants in
hemin transport to cells, a cellular mechanism should
exist to down-regulate excess of heme transported as
a complex with lipoproteins. The natural enzyme to
take care of hemin excess is heme oxygenase. The
recent data reveal elevated expression of heme oxy-
genase-1 (HO-1) in endothelium, foam cells/macro-
phages and smooth muscle cells of thickened intima
in atherosclerotic lesions from both humans and ex-
perimental animals [42,43]. Moreover, HO-1 overex-
pression inhibited formation of the lesions [43]. Fur-
ther studies are needed to evaluate whether HO-1
expression in atherosclerotic tissue relates to lipopro-
tein-associated transport of hemin into the cells.
In summary, the most important result of the
present study is the ¢nding of extensive hemin transit
via lipoproteins in plasma as well as existence of
meaningful residual hemin retained within lipopro-
teins in steady state. Under conditions of oxidative
stress, the hemin-induced lipoprotein oxidation may
have pro-atherogenic e¡ects.
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Appendix
The hemin^HPX binding constant of 1011 M31
was obtained in the present study by dividing the
association rate constant by the dissociation rate
constant (Table 2), whereas Hrkal et al. [33] calcu-
lated the hemin^HPX binding constant based on the
data on hemin transfer from hemoglobin to HPX
and the known hemin^globin binding constant of
1013 M31. From the fact that the equilibrium con-
stant of hemin transfer from hemoglobin to HPX
was 10, the hemin^HPX binding constant was con-
cluded to be 1014 M31. Since the hemin transfer from
hemoglobin to another plasma protein, albumin, has
BBADIS 61834 10-6-99
Y.I. Miller, N. Shaklai / Biochimica et Biophysica Acta 1454 (1999) 153^164162
also been reported [44], one is inclined to assume that
hemin^HSA binding constant will be also above 1013
M31. However, it turned out that the hemin^HSA
binding constant is only 108^109 M31 ([8,10]; Table
2).
Determination of binding constant from transfer
data would be correct only for a single-step type of
hemin association with either globin, HPX or HSA,
which is not the case: hemin association with these
proteins is a complex process. For globin, an initial
hydrophobic interaction between the hemin and the
globin apolar cavity accounts for 105^107 of the
binding constant, and additional factor of 106^108
comes on the second step from a Fe3^His bond
and speci¢c hemin interactions with conserved amino
acids [23]. Thus, hemin binding to globin proceeds
via an intermediate complex (GLB^h)* (reaction 3,
see below). Similarly, initial hemin binding to HPX is
followed by a rearrangement in protein binding site
thereby strengthening hemin^HPX binding [31]. In
the case of albumin, following initial hydrophobic
interaction with hemin, iron coordination stabilizes
the hemin^albumin complex. This was concluded
from the 2^3 orders of magnitude di¡erence in albu-
min binding among hemin (Fe-protoporphyrin), Sn-
protoporphyrin and apo-protoporphyrin [45]. Reac-
tion 4 displays formation of intermediate (HSA^h)*
and ¢nal HSA^h complexes.
Because of a very high di¡erence in overall binding
constants of globin and HSA with hemin
(KG1 K
G
2 EKA1 KA2 ), it is clear that no hemin exchange
will occur between the ¢nal GLB^h and HSA^h
complexes. Alternatively, hemin exchange between
the intermediate (GLB^h)* and (HSA^h)* complexes
would probably proceed, because KG1 and K
A
1 are of
the same order [23].
Coming back to the globin/HPX hemin transfer,
this transfer should also proceed between the inter-
mediate rather than between the ¢nal hemin^protein
complexes. The equilibrium constant for hemin
transfer from hemoglobin to hemopexin therefore
presents a ratio between the a⁄nity constants of in-
termediate (GLB^h)* and (HPX^h)* complexes
rather than between overall binding constants. This
conclusion suggests that the previously reported
hemin^HPX binding constant of 1014 M31 [33] has
been highly overestimated, and is therefore unsuit-
able as a reference for the constant of 1011 M31
measured in the present study.
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